Defence

PNC Financial Services Group Inc. purchased 893 shares of DexCom, Inc. (NASDAQ:DXCM)


PNC Financial Services Group Inc. increased its stake in shares of DexCom, Inc. (NASDAQ: DXCMGet a rating) by 12.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 8,320 shares of the medical devices company’s stock after buying an additional 893 shares during the period. PNC Financial Services Group Inc.’s participation. in DexCom were worth $4,256,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Baillie Gifford & Co. grew its holdings in DexCom by 1.0% in the first quarter. Baillie Gifford & Co. now owns 4,554,293 shares of the medical device company’s stock valued at $2,329,976,000 after purchasing an additional 45,107 shares during the period. Jennison Associates LLC increased its position in DexCom by 83.4% during the 1st quarter. Jennison Associates LLC now owns 2,600,283 shares of the medical device company’s stock valued at $1,330,305,000 after buying an additional 1,182,632 shares in the last quarter. Capital Research Global Investors boosted its holdings in DexCom by 55.2% in the fourth quarter. Capital Research Global Investors now owns 2,374,545 shares of the medical devices company’s stock valued at $1,275,020,000 after acquiring an additional 844,916 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of DexCom by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 1,868,331 shares of the medical device company’s stock valued at $1,000,773,000 after acquiring an additional 73,778 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of DexCom during the fourth quarter valued at $410,670,000. 92.34% of shares are held by hedge funds and other institutional investors.

Insider trading

In related news, the director Stephen Robert Pacelli sold 1,000 shares of the stock in a transaction that occurred on Thursday, June 23rd. The shares were sold at an average price of $72.55 for a total amount of $72,550.00. Following the completion of the sale, the director now directly owns 139,700 shares in the company, valued at approximately $10,135,235. The transaction was disclosed in a legal filing with the Securities and Exchange Commission, which is available at this hyperlink. In related news, the director Stephen Robert Pacelli sold 1,000 shares of the company’s stock in a transaction on Thursday, June 23rd. The shares were sold at an average price of $72.55 for a total amount of $72,550.00. Following the completion of the transaction, the director now owns 139,700 shares in the company, valued at approximately $10,135,235. The sale was disclosed in a legal filing with the Securities and Exchange Commission, which is available at this link. Also, CFO Jeremy M. Sylvain sold 600 shares of the firm’s stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $301.57, for a total amount of $180,942.00. Following the sale, the chief financial officer now directly owns 17,408 shares in the company, valued at $5,249,730.56. Disclosures for this sale can be found here here. Insiders sold a total of 3,600 shares of company stock valued at $420,772 over the last ninety days. Corporate insiders own 0.41% of the company’s shares.

DexCom shares fell 1.3%

DXCM opened at $82.00 on Friday. The 50 day SMA is $83.00, and the 200 day SMA is $93.04. The company has a market cap of $32.19 billion, a PE ratio of 170.84, a PEG ratio of 3.38 and a beta of 1.03. DexCom, Inc. has a 1 year low of $66.89 and a 1 year high of $164.86. The company has a current ratio of 4.72, a gearing ratio of 4.30, and a debt-to-equity ratio of 0.87.

DexCom (NASDAQ: DXCMGet a rating) last announced earnings results on Thursday, July 28. The medical devices company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). DexCom’s return on equity was 11.79% and its net margin was 7.47%. The company had revenue of $696.20 million for the quarter, compared to the consensus estimate of $709.33 million. For the same period last year, earnings per share were $0.19. DexCom’s revenue for the quarter was up 17.0% compared to the same quarter last year. Overall, equities analysts predict that DexCom, Inc. will post 0.79 earnings per share for the current year.

Changes in analysts’ ratings

DXCM has been the topic of several recent analyst reports. BTIG Research cut their price target on shares of DexCom from $135.00 to $105.00 and set a “buy” rating on the stock in a research report on Friday, June 24th. Sanford C. Bernstein began coverage on shares of DexCom in a research report on Friday, July 15th. They set an “outperform” rating and a $105.00 price target for the company. Wells Fargo & Company cut their price objective on DexCom from $144.00 to $102.00 in a research report on Friday, July 29th. Cowen restated a “buy” rating and issued a $85.00 target price on shares of DexCom in a research note on Friday, July 29th. Finally, Piper Sandler cut their price objective on DexCom from $120.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, July 29th. Two investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. The company presently has an average rating of “Moderate Buy” and an average target price of $115.23, according to MarketBeat.

DexCom Company Profile

(Get a rating)

DexCom, Inc, a medical device company, focuses on the design, development and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company markets its systems for use by people with diabetes as well as for use by healthcare providers. Its products include the DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which allows invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, which is designed to replace fingerstick blood glucose testing for diabetes management decisions; and Dexcom Share, a remote monitoring system.

Selected stories

Institutional Ownership of DexCom (NASDAQ:DXCM) by Quarter



Get news and ratings for DexCom daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DexCom and related companies. MarketBeat.com’s FREE Daily E-Newsletter.

https://www.defenseworld.net/2022/09/04/pnc-financial-services-group-inc-purchases-893-shares-of-dexcom-inc-nasdaqdxcm.html PNC Financial Services Group Inc. purchased 893 shares of DexCom, Inc. (NASDAQ:DXCM)

Back to top button